Evidence map›Paper›PMID 22031938›Full record

ArticleJournal of virology2012

Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals.

Rafael Contreras-Galindo, Mark H Kaplan, Angie C Contreras-Galindo, Marta J Gonzalez-Hernandez, Ilaria Ferlenghi, Fabiola Giusti, Eric Lorenzo, Scott D Gitlin, Michael H Dosik, Yasuhiro Yamamura and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Rafael Contreras-GalindoDepartment of Internal Medicine, and Programs in Cancer Biology, Immunology, and Cellular and Molecular Biology, University of Michigan, Ann Arbor, Michigan, USA.
Mark H Kaplan
Angie C Contreras-Galindo
Marta J Gonzalez-Hernandez
Ilaria Ferlenghi
Fabiola Giusti
Eric Lorenzo
Scott D Gitlin
Michael H Dosik
Yasuhiro Yamamura
David M Markovitz
Stony Brook University · USUniversity of Michigan–Ann Arbor · USNovartis (Italy) · ITVeterans Health Administration · US

Funding

VIRAL SEQUENCES IN PEDIATRIC HIV INFECTION IN PRG12RR003050 · NCRR · PONCE SCHOOL OF MEDICINE · PI ARMSTRONG, RAUL A · 1985 to 2011
$28.1M
Replication of Human Endogenous Retroviruses in Modern HumansR01CA144043 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARKOVITZ, DAVID MICHAEL · 2009 to 2013
$6.4M
CXC Chemokines and HIV PathogenesisR01AI062248 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARKOVITZ, DAVID MICHAEL · 2005 to 2009
$1.6M
NCI NIH HHS R01 CA144043NCRR NIH HHS G12 RR003050NCRR NIH HHS G12RR03050NIAID NIH HHS R01 AI062248
6 · The paper itself

Abstract

We previously reported finding the RNA of a type K human endogenous retrovirus, HERV-K (HML-2), at high titers in the plasma of HIV-1-infected and cancer patients (R. Contreras-Galindo et al., J. Virol. 82:9329-9236, 2008.). The extent to which the HERV-K (HML-2) proviruses become activated and the nature of their activated viral RNAs remain important questions. Therefore, we amplified and sequenced the full-length RNA of the env gene of the type 1 and 2 HERV-K (HML-2) viruses collected from the plasma of seven HIV-1-infected patients over a period of 1 to 3 years and from five breast cancer patients in order to reconstruct the genetic evolution of these viruses. HERV-K (HML-2) RNA was found in plasma fractions of HIV-1 patients at a density of ∼1.16 g/ml that contained both immature and correctly processed HERV-K (HML-2) proteins and virus-like particles that were recognized by anti-HERV-K (HML-2) antibodies. RNA sequences from novel HERV-K (HML-2) proviruses were discovered, including K111, which is specifically active during HIV-1 infection. Viral RNA arose from complete proviruses and proviruses devoid of a 5' long terminal repeat, suggesting that the expression of HERV-K (HML-2) RNA in these patients may involve sense and antisense transcription. In HIV-1-infected individuals, the HERV-K (HML-2) viral RNA showed evidence of frequent recombination, accumulation of synonymous rather than nonsynonymous mutations, and conserved N-glycosylation sites, suggesting that some of the HERV-K (HML-2) viral RNAs have undergone reverse transcription and are under purifying selection. In contrast, HERV-K (HML-2) RNA sequences found in the blood of breast cancer patients showed no evidence of recombination and exhibited only sporadic viral mutations. This study suggests that HERV-K (HML-2) is active in HIV-1-infected patients, and the resulting RNA message reveals previously undiscovered HERV-K (HML-2) genomic sequences.

Indexed as

Endogenous Retrovirusesenv Gene Products, Human Immunodeficiency VirusGenome, ViralHIV-1HIV InfectionsHumansMolecular Sequence DataPhylogenyRecombination, GeneticReverse TranscriptionRNA, Viralenv Gene Products, Human Immunodeficiency VirusRNA, Viral

Identifiers

PMID22031938
PMCPMC3255917
OpenAlexW2063547657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.